Show simple item record

dc.contributor.authorIbrahim, Mohamed Nabil
dc.contributor.authorElfiky, Abdo Abdellah
dc.date.accessioned2022-06-20T08:19:27Z
dc.date.available2022-06-20T08:19:27Z
dc.date.issued2021-05-10
dc.identifier.citationIbrahim, M. N., & Elfiky, A. A. (2021). Sofosbuvir May be a Potential Anti-SARS-CoV-2 RdRp Drug. American Journal of Biochemistry and Biotechnology, 17(2), 205–207. doi:10.3844/ajbbsp.2021.205.207
dc.identifier.issn1558-6332
dc.identifier.issn1553-3468
dc.identifier.doi10.3844/ajbbsp.2021.205.207
dc.identifier.urihttp://hdl.handle.net/10754/679205
dc.description.abstractThe Coronavirus Diseases 2019 (COVID-19) seriously affecting human health all over the world. More than 107 M people are reported positive for SARS-CoV-2, the virus causing COVID-19 pneumonia, from which +2.3 M died. Nucleotide Inhibitors (NI) have promising results in terms of its efficacy against different viral polymerases, including the Hepatitis C Virus (HCV) Non-Structural Protein 5 B (NS5B) RNA dependent RNA polymerase (RdRp) 1. Thus, the non-structural protein 12 (nsp12) RdRp of the human coronavirus represents an attractive target to develop a possible therapeutic agent. Sofosbuvir proved itself as a potential anti-SARS-CoV-2 RdRp and could inhibit viral replication and infection propagation.
dc.description.sponsorshipComputational support from the King Abdullah University of Science and Technology (KAUST HPC allocation grant “K1482”) and COVID-19 Grant by Cairo University , is acknowledged.
dc.publisherScience Publications
dc.relation.urlhttps://thescipub.com/abstract/10.3844/ajbbsp.2021.205.207
dc.titleSofosbuvir may be a potential anti-sars-cov-2 rdrp drug
dc.typeArticle
dc.identifier.journalAmerican Journal of Biochemistry and Biotechnology
dc.contributor.institutionDepartment of Clinical Laboratory Sciences, Jouf University, Saudi Arabia
dc.contributor.institutionDepartment of Microbiology, Ain Shams University, Egypt
dc.contributor.institutionDepartment of Biophysics, Cairo University, Egypt
dc.identifier.volume17
dc.identifier.issue2
dc.identifier.pages205-207
dc.identifier.eid2-s2.0-85107233257
kaust.acknowledged.supportUnitKAUST HPC allocation grant “K1482


This item appears in the following Collection(s)

Show simple item record